Shares of KalVista (KALV) plunged initially on the report, but have recovered to be down 16c, or 1%, to $11.77.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista trading resumes
- KalVista trading halted, volatility trading pause
- Positive Outlook on KalVista Pharmaceuticals’ Sebetralstat Approval Despite FDA Decision Delay
- Optimistic Buy Rating for KalVista Pharmaceuticals Amid FDA Delay
- KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA